Zacks Investment Research Comments on Edesa Biotech, Inc.’s Q1 2022 Earnings (NASDAQ:EDSA)

Related Articles

Edesa Biotech, Inc. (NASDAQ: EDSA) – Analysts at Zacks Investment Research released their first quarterly earnings per share (EPS) estimates for 2022 for Edesa Biotech in a report released on Thursday, January 6th. Zacks D.Bouts investment research analyst expects the company to post earnings per share of ($ 0.40) for the quarter. Zacks Investment Research also released estimates for Edesa Biotech’s second quarter 2022 earnings ($ 0.41) EPS, 32222 earnings at ($ 0.41) EPS and Q4 2022 at EPS ($ 0.42).

Separately, HC Wainwright received coverage of Edesa Biotech shares in a research report on Monday, December 20th. They set a “buy” rating and a price target of $ 16.00 per share.

Shares of EDSA stock It opened at $ 5.38 on Monday. Edesa Biotech has a one-year low of $ 4.15 and a one-year low of $ 12.00. The company’s simple moving average for 50 days is $ 6.32 and the simple moving average of its 200 days is $ 6.10. The stock has a market capitalization of $ 72.73 million, a price-to-earnings ratio of 4.98 and a beta of 0.56. Edesa Biotech (NASDAQ: EDSA) recently released its quarterly earnings data on Tuesday, December 28th. The company reported ($ 0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($ 0.37) by $ 0.10.

A number of institutional investors have recently bought and sold EDSA shares. Vanguard Group Inc. Increased its stake in Edesa Biotech by 88.9% during the second quarter. Vanguard Group Inc. Holds 109,158 shares of the company worth $ 576,000 after acquiring an additional 51,369 shares during the period. Geode Capital Management LLC increased its holdings in Edesa Biotech by 153.3% in the second quarter. Geode Capital Management LLC now holds 74,032 shares of the company worth $ 390,000 after acquiring an additional 44,803 shares during the period. 180 Wealth Advisors LLC acquired a new stake in Edesa Biotech during the second quarter worth approximately $ 70,000. Virtu Financial LLC increased its position in Edesa Biotech by 17.4% in the second quarter. Virtu Financial LLC now owns 18,938 shares of the company worth $ 100,000 after acquiring an additional 2,800 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Edesa Biotech in the third quarter worth approximately $ 115,000. Hedge funds and other institutional investors hold 1.98% of the company’s shares.

On Edesa Biotech

Edesa Biotech, Inc. is a biopharmaceutical company that focuses on the purchase, development and commercialization of drugs in clinical stages for inflammatory diseases and diseases related to the immune system with clear medical needs. The company’s product candidate, EB01 is a non-steroidal anti-inflammatory treatment for chronic allergic contact dermatitis (ACD), a common and potentially debilitating condition and occupational disease.

See also: Bollinger Bands

This instant news alert was created using narrative scientific technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send questions or comments about this story to [email protected]

Is it worth investing $ 1,000 in Edesa Biotech right now?

Before you consider Edesa Biotech, you would like to hear it.

MarketBeat tracks the top Wall Street analysts and the best performance and stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that leading analysts are quietly whispering to their clients to buy now before the broad market takes over … and Edesa Biotech was not on the list.

While Edesa Biotech currently has a “buy” rating among analysts, top-ranked analysts believe these five stocks are better buys.

Watch the 5 stocks here




Please enter your comment!
Please enter your name here

Popular Articles